- Vector Science & Therapeutics (TSXV:PAIN) appointed NBA Champion Gary Payton II, currently a guard for the Golden State Warriors, as Chief Athletic Ambassador for Valor, the company’s sports medicine division.
- The Wisconsin-based biomechanical device and drug delivery company is focused on site-directed interventions that enhance pain management and drive musculoskeletal regeneration.
- Vector Science stock has added 575 per cent since inception in April 2026.
Vector Science & Therapeutics (TSXV:PAIN) appointed NBA Champion Gary Payton II, currently a guard for the Golden State Warriors, as Chief Athletic Ambassador for Valor, the company’s sports medicine division, which seeks to leverage the professional athlete market to enhance the company’s biomechanical and transdermal peptide delivery platforms.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Payton II, son of Hall of Famer Gary Payton, will be tasked with serving as the face of Valor in the NBA and across professional sports, educating athletes about optimizing their approaches to soft tissue injuries, longevity and pain management.
According to Monday’s news release, soft tissue injuries are one of professional basketball’s most pressing unmet needs, accounting for 62 per cent of orthopedic injuries among NBA players, with calf injuries increasing from 18 in the 2010-11 season to 86 in 2025-2026, including 13 different players suffering multiple calf injuries this year alone, a figure higher than any year on record.
Payton II is the founder of the GPII Foundation, a nonprofit supporting children with dyslexia, a challenge Payton II faced personally, providing them with early screening, educational resources and certified assessments.
The news follows the appointment of 2016 World Series Champion Dexter Fowler as Chief Athletic Officer earlier this month, expanding the company’s reach into the Big Leagues.
Leadership commentary
“Injury and pain are part of the game. What you use to manage injury and pain doesn’t have to come with consequences you’ll spend the rest of your life dealing with. I want the players I compete with…and the ones coming up behind us…to have something better. That’s Valor. That’s why I’m here,” Payton II said in a statement.
“Gary is still competing every night, living this firsthand. And when he’s not on the court, he’s giving back. That combination of talent, character and genuine heart is exactly who Valor needed carrying this mission,” added Darryl Drake Jr., President of Valor.
About Vector Science & Therapeutics
Vector Science & Therapeutics is a Wisconsin-based biomechanical device and drug delivery company focused on site-directed interventions that enhance pain management and drive musculoskeletal regeneration.
Vector Science stock (TSXV:PAIN) is up by 1.21 per cent trading at C$2.50 as of 9:46 am ET. The stock has added 575 per cent since inception in April 2026.
Join the discussion: Find out what investors are saying about Gary Payton II and this healthcare stock on the Vector Science & Therapeutics Corp. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
